Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Modulating ApoE Signalling to Reduce Brain Inflammation, deLirium and postopErative Cognitive Dysfunction (MARBLE): A Phase 2 Trial to Evaluate the Efficacy and Feasibility of CN-105 in Preventing Postoperative Cognitive Dysfunction and Delirium

NCT03802396 is registered in ClinicalTrials.gov with Miles Berger, MD PhD as lead sponsor.

NCT NCT03802396
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03802396 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Modulating ApoE Signalling to Reduce Brain Inflammation, deLirium and postopErative Cognitive Dysfunction (MARBLE): A Phase 2 Trial to Evaluate the Efficacy and Feasibility of CN-105 in Preventing Postoperative Cognitive Dysfunction and Delirium
Lead sponsor
Miles Berger, MD PhD
Phase
Phase 2
Overall status
Completed
Start date
July 15, 2018
Completion date
December 28, 2022
Enrollment
203 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

postoperative cognitive dysfunction, postoperative delirium